Jasper Therapeutics, Inc.

BiotechnologyBiotechnologyClinical-StagePrivate Placement

📍 Menlo Park, CA, USA• Founded 2018• 51-100 employees

StreetZero Signal 70

Be the first to signal interest

About Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel antibody therapies targeting c-Kit to address diseases such as chronic spontaneous urticaria and lower to intermediate risk myelodysplastic syndromes. The company is also focused on enabling safer conditioning agents and therapeutics to allow for expanded use of curative hematopoietic stem cell transplants and gene therapies. Jasper Therapeutics' lead compound, JSP191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem cell transplant.

LATEST FUNDINGPrivate Placement (Form D)

$132.0M

Announced 2026-08-05

TOTAL RAISED$131,999,611

🔒

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for Jasper Therapeutics, Inc..

Create free account Sign in

Free plan includes 3 full deal profiles every month.

IN THE NEWS

EMPLOYEES51-100

FOUNDED2018

HQMenlo Park, CA, USA

Industry

Biotechnology

Investors

Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.

Key highlights

Jasper Therapeutics, Inc. has raised $131,999,611 in a Private Placement round
The company is developing novel antibody therapies targeting c-Kit
Jasper Therapeutics' lead compound, JSP191, is in clinical development as a conditioning antibody